{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:48:20Z","timestamp":1789015700978,"version":"build-2803163510"},"reference-count":30,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Radiotherapy (RT) is typically incorporated into the treatment of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), although it remains unknown whether chemotherapy alone may be suitable in select patients. We evaluated outcomes of limited-stage NLPHL at BC Cancer on the basis of era-specific guidelines: routine RT era, 1995 to 2005 (n = 36), combined modality with 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy followed by RT or RT alone; positron emission tomography (PET) era, after 2005 (n = 63), ABVD alone (4 cycles) if the PET scan after the second cycle of ABVD (PET2) is negative, or treatment is changed to RT if PET2 is positive. Median age of patients was 38 years (range, 16-82 years), 73% were male, and 43% had stage II. With a median follow-up of 10.5 years for all patients, 5-year progression-free survival (PFS) was 93% and was 97% for overall survival (OS), with no difference by treatment era (PFS, P = .13; OS, P = .35). For the 49 patients who had a PET2 scan, 86% were PET negative and 14% were PET positive by Deauville criteria with 5-year PFS rates of 92% and 80% (P = .70), respectively. This is the largest study of a PET-adapted approach in NLPHL and supports that ABVD alone may be a viable option in select patients with a negative PET2 scan, with consideration of acute and long-term toxicities.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004375","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T21:57:36Z","timestamp":1630015056000},"page":"3647-3655","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3512-8608","authenticated-orcid":false,"given":"Phoebe T. M.","family":"Cheng","sequence":"first","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4625-3009","authenticated-orcid":false,"given":"Diego","family":"Villa","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2712-7189","authenticated-orcid":false,"given":"R. Petter","family":"Tonseth","sequence":"additional","affiliation":[{"name":"Division of Radiology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4727-1425","authenticated-orcid":false,"given":"Alina S.","family":"Gerrie","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-6480","authenticated-orcid":false,"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2040-4630","authenticated-orcid":false,"given":"Tom","family":"Pickles","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea C.","family":"Lo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9364-9391","authenticated-orcid":false,"given":"Pedro","family":"Farinha","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Division of Pathology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1295-3258","authenticated-orcid":false,"given":"Jeffrey W.","family":"Craig","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Division of Pathology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham W.","family":"Slack","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Division of Pathology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Division of Pathology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"B\u00e9nard","sequence":"additional","affiliation":[{"name":"Division of Radiology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Wilson","sequence":"additional","affiliation":[{"name":"Division of Radiology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Skinnider","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Division of Pathology, BC Cancer, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1361-7531","authenticated-orcid":false,"given":"Joseph M.","family":"Connors","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-9863","authenticated-orcid":false,"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer and Department of Medical Oncology,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"issue":"20","key":"2021092415294292300_B1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"issue":"5","key":"2021092415294292300_B2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2009.24.9516","article-title":"Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin\u2019s lymphoma","volume":"28","author":"Al-Mansour","year":"2010","journal-title":"J Clin Oncol."},{"issue":"3","key":"2021092415294292300_B3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.24819","article-title":"Nodular, lymphocyte-predominant Hodgkin lymphoma: a long-term study and analysis of transformation to diffuse large B-cell lymphoma in a cohort of 164 patients from the Adult Lymphoma Study Group","volume":"116","author":"Biasoli","year":"2010","journal-title":"Cancer."},{"issue":"23","key":"2021092415294292300_B4","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1182\/blood-2013-12-541078","article-title":"Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis","volume":"123","author":"Xing","year":"2014","journal-title":"Blood."},{"key":"2021092415294292300_B5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/hon.2226","article-title":"XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma","volume":"33","author":"Advani","year":"2015","journal-title":"Hematol Oncol."},{"issue":"1","key":"2021092415294292300_B6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/bjh.15616","article-title":"Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma","volume":"184","author":"Spinner","year":"2019","journal-title":"Br J Haematol."},{"key":"2021092415294292300_B7","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann Oncol."},{"issue":"6","key":"2021092415294292300_B8","doi-asserted-by":"crossref","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","article-title":"Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Hoppe","year":"2020","journal-title":"J Natl Compr Canc Netw."},{"issue":"2","key":"2021092415294292300_B9","doi-asserted-by":"crossref","first-page":"E429","DOI":"10.1016\/j.ijrobp.2017.06.1631","article-title":"Observation after surgery for stage IA nodular lymphocyte-predominant Hodgkin lymphoma","volume":"99","author":"Jain","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"20","key":"2021092415294292300_B10","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood-2018-10-877761","article-title":"Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"133","author":"Borchmann","year":"2019","journal-title":"Blood."},{"issue":"3","key":"2021092415294292300_B11","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/s41375-019-0609-3","article-title":"Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group","volume":"34","author":"Eichenauer","year":"2020","journal-title":"Leukemia."},{"issue":"9","key":"2021092415294292300_B12","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","article-title":"Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"32","author":"Advani","year":"2014","journal-title":"J Clin Oncol."},{"issue":"32","key":"2021092415294292300_B13","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1200\/JCO.2007.15.1001","article-title":"Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin\u2019s lymphoma: a question of field size","volume":"26","author":"Campbell","year":"2008","journal-title":"J Clin Oncol."},{"issue":"12","key":"2021092415294292300_B14","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.3324\/haematol.2018.196782","article-title":"Interim PET-directed therapy in limited-stage Hodgkin lymphoma initially treated with ABVD","volume":"103","author":"Villa","year":"2018","journal-title":"Haematologica."},{"issue":"25","key":"2021092415294292300_B15","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med."},{"issue":"5","key":"2021092415294292300_B16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol."},{"issue":"17","key":"2021092415294292300_B17","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med."},{"issue":"17","key":"2021092415294292300_B18","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1182\/blood-2011-07-365932","article-title":"Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome","volume":"118","author":"Savage","year":"2011","journal-title":"Blood."},{"issue":"7","key":"2021092415294292300_B19","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med."},{"issue":"3","key":"2021092415294292300_B20","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/bjh.14567","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry","volume":"177","author":"Molin","year":"2017","journal-title":"Br J Haematol."},{"issue":"26","key":"2021092415294292300_B21","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1182\/blood.2019003877","article-title":"Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG","volume":"135","author":"Binkley","year":"2020","journal-title":"Blood."},{"issue":"5","key":"2021092415294292300_B22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/bjh.14861","article-title":"Nodular lymphocyte predominant Hodgkin lymphoma in USA between 2000 and 2014: an updated analysis based on the SEER data","volume":"182","author":"Shivarov","year":"2018","journal-title":"Br J Haematol."},{"issue":"2","key":"2021092415294292300_B23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/10428194.2015.1065978","article-title":"Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival","volume":"57","author":"Parikh","year":"2016","journal-title":"Leuk Lymphoma."},{"issue":"26","key":"2021092415294292300_B24","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1200\/JCO.2014.60.4363","article-title":"Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group","volume":"33","author":"Eichenauer","year":"2015","journal-title":"J Clin Oncol."},{"issue":"1","key":"2021092415294292300_B25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ijrobp.2015.02.012","article-title":"Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis","volume":"92","author":"Gerber","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"2021092415294292300_B26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2015.02.001","article-title":"Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era","volume":"92","author":"King","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2021092415294292300_B27","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1200\/JCO.2018.36.15_suppl.7535","article-title":"Limited stage nodular lymphocyte predominant Hodgkin lymphoma (NLPHL): A subgroup analysis of the HD.6 clinical trial","volume":"36","author":"Monteith","year":"2018","journal-title":"J Clin Oncol."},{"issue":"4","key":"2021092415294292300_B28","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1182\/blood-2017-02-766121","article-title":"Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma","volume":"130","author":"Fanale","year":"2017","journal-title":"Blood."},{"issue":"26","key":"2021092415294292300_B29","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1182\/blood-2013-07-515825","article-title":"The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)","volume":"122","author":"Hartmann","year":"2013","journal-title":"Blood."},{"issue":"6","key":"2021092415294292300_B30","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1111\/bjh.16109","article-title":"Frontline management of nodular lymphocyte predominant Hodgkin lymphoma - a retrospective UK multicentre study","volume":"186","author":"Wilson","year":"2019","journal-title":"Br J Haematol."}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2022007162","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/18\/3647\/1823577\/advancesadv2021004375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/18\/3647\/1823577\/advancesadv2021004375.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T19:38:00Z","timestamp":1632512280000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/18\/3647\/476696\/Outcome-of-limited-stage-nodular-lymphocyte"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":30,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,9,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004375","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/bloodadvances.2022007162","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,26]]}}}